Pharmacoeconomics is a newly developed discipline in China. Economic assessment is increasingly used as supportive evidence driving pricing and reimbursement decisions. Nevertheless, guidelines are necessary to homogenise their practice and promote their use. Among the different guidelines that have been published, two published in 2006 and in 2011 significantly support the implementation of pharmacoeconomics in China. Since multinational pharmaceutical companies are increasingly present in the Chinese market, this tends to increase the spread of such publications.